Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Myofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions
Sean M. Fortier, Loka R. Penke, Dana King, Tho X. Pham, Giovanni Ligresti, Marc Peters-Golden
Sean M. Fortier, Loka R. Penke, Dana King, Tho X. Pham, Giovanni Ligresti, Marc Peters-Golden
View: Text | PDF
Research Article Cell biology Pulmonology

Myofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions

  • Text
  • PDF
Abstract

Myofibroblasts are the major cellular source of collagen, and their accumulation — via differentiation from fibroblasts and resistance to apoptosis — is a hallmark of tissue fibrosis. Clearance of myofibroblasts by dedifferentiation and restoration of apoptosis sensitivity has the potential to reverse fibrosis. Prostaglandin E2 (PGE2) and mitogens such as FGF2 have each been shown to dedifferentiate myofibroblasts, but — to our knowledge — the resultant cellular phenotypes have neither been comprehensively characterized or compared. Here, we show that PGE2 elicited dedifferentiation of human lung myofibroblasts via cAMP/PKA, while FGF2 utilized MEK/ERK. The 2 mediators yielded transitional cells with distinct transcriptomes, with FGF2 promoting but PGE2 inhibiting proliferation and survival. The gene expression pattern in fibroblasts isolated from the lungs of mice undergoing resolution of experimental fibrosis resembled that of myofibroblasts treated with PGE2 in vitro. We conclude that myofibroblast dedifferentiation can proceed via distinct programs exemplified by treatment with PGE2 and FGF2, with dedifferentiation occurring in vivo most closely resembling the former.

Authors

Sean M. Fortier, Loka R. Penke, Dana King, Tho X. Pham, Giovanni Ligresti, Marc Peters-Golden

×

Figure 7

PGE2 and FGF2 have opposite effects on myofibroblast proliferation and apoptosis.

Options: View larger image (or click on image) Download as PowerPoint
PGE2 and FGF2 have opposite effects on myofibroblast proliferation and a...
(A) CCL210 myofibroblasts were treated with PGE2, FGF2, or PGE2 + FGF2 for 24–72 hours. qPCR analysis of the proliferation gene FOXM1 was performed at 48 hours, while CCNB2, CCND1, and CDKN1C were assessed at 72 hours (top panel). qPCR analysis of the antiapoptotic gene SERPINE1 was performed at 24 hours, while BIRC5 and MYC were assessed at 48 hours; the proapoptotic gene CASP9 was assessed at 72 hours. (B) Proliferation was assessed 96 hours following treatment with PGE2 and/or FGF2 by CyQUANT Cell Proliferation Assay. (C) Apoptosis sensitivity was assessed by measuring total and cleaved CASP3 and PARP by Western blot analysis in myofibroblasts 5 days following addition of PGE2 and/or FGF2, followed by treatment with the death receptor ligand anti-Fas. CASP3 was measured 30 minutes and PARP 1 hour following anti-Fas treatment. Densitometry represents ratio of cleaved products to total protein. Relative fold changes of indicated genes measured by qPCR are normalized to GAPDH. Data are presented as mean ± SEM. Data points represent replicate samples from 3 (A and C) or 4 (B) experiments. Lines indicate conditions being compared. *P < 0.05, compared with untreated myofibroblast; 1-way ANOVA. De-diff, dedifferentiation.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts